本帖最后由 老马 于 2012-1-13 21:20 编辑
( N" N5 K# i7 x" J+ Y! M' x8 k1 A5 K' |) W: X! J9 `2 |
爱必妥和阿瓦斯丁的比较4 `$ f. E# Z4 n9 y: ?: q
/ h; ]4 {$ i$ e" c7 y3 Z; G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/; q" c2 V* c4 Y, b
# l; [% e& p3 p$ T; m4 ~' R
- |# A3 d7 T/ n+ q1 ]* h5 g, `# ? t( ^http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# _9 r: P; t! ~
==================================================
% ]2 i U5 t( m) n, x bOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
( C) U) F/ {+ v B% T7 O5 X! nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* j# E m. R" g% U5 UResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 V1 V% ~/ Q, W. }6 l& f! p
|